|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.96 HKD | -0.20% |
|
+7.55% | +9.60% |
| 06-16 | Zai Lab Receives EU Orphan Drug Designation for Lung Cancer Drug | MT |
| 06-10 | Asian Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading | MT |
| Market Cap | 2.15B 16.85B 1.88B 1.73B 1.61B 3.05B 205B 3.1B 20.72B 8.05B 101B 8.06B 7.89B 346B | P/E 2026 * |
-8.63x | P/E 2027 * | -10.3x |
|---|---|---|---|---|---|
| Enterprise Value | 1.71B 13.37B 1.49B 1.37B 1.28B 2.42B 162B 2.46B 16.45B 6.39B 79.8B 6.4B 6.26B 275B | EV / Sales 2026 * |
3.8x | EV / Sales 2027 * | 2.96x |
| Free-Float |
95.17% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Zai Lab Limited
| 1 day | -0.20% | ||
| 1 week | +7.55% | ||
| Current month | +3.46% | ||
| 1 month | +12.82% | ||
| 3 months | -5.20% | ||
| 6 months | +10.16% | ||
| Current year | +9.60% |
| 1 week | 13.74 |  | 15.55 |
| 1 month | 12.49 | | 15.55 |
| Current year | 12.31 | | 20.42 |
| 1 year | 12.31 | | 32.35 |
| 3 years | 10.56 | | 35.5 |
| 5 years | 10.56 | | 142 |
| 10 years | 10.56 | | 151.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
Ying Du
CEO | Chief Executive Officer | 61 | 2014-03-31 |
Ya jing Chen
DFI | Director of Finance/CFO | 58 | 2023-07-06 |
Rafael Amado
PSD | President | 62 | 2022-11-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Ying Du
CHM | Chairman | 61 | 2014-03-31 |
John Diekman
BRD | Director/Board Member | 83 | 2016-12-31 |
Peter Wirth
BRD | Director/Board Member | 75 | 2016-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.20% | +7.55% | - | - | 2.15B | |
| +4.73% | +3.38% | +19.53% | -8.89% | 66.56B | |
| -1.93% | +0.39% | +53.64% | +226.01% | 56.51B | |
| +1.07% | +42.10% | +42.10% | +42.10% | 42.98B | |
| +3.45% | +6.04% | -49.82% | -55.95% | 40.46B | |
| +3.04% | +0.04% | +62.66% | -24.29% | 31.91B | |
| +10.01% | +18.57% | +161.59% | -34.48% | 31.65B | |
| +2.68% | +2.73% | +70.72% | +88.24% | 23.35B | |
| +2.87% | +16.83% | +1.86% | +165.26% | 19.46B | |
| -0.13% | +2.75% | +66.32% | +127.01% | 17.18B | |
| Average | +2.56% | +8.76% | +47.62% | +58.33% | 36.67B | |
| Weighted average by Cap. | +2.77% | +7.31% | +42.61% | +52.47% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 449M 3.52B 392M 360M 336M 637M 42.72B 647M 4.33B 1.68B 21B 1.68B 1.65B 72.36B | 596M 4.67B 521M 478M 446M 846M 56.71B 859M 5.74B 2.23B 27.87B 2.24B 2.19B 96.05B |
| Net income | -241M -1.89B -211M -194M -180M -342M -22.94B -347M -2.32B -903M -11.27B -904M -885M -38.85B | -156M -1.23B -137M -126M -117M -222M -14.9B -226M -1.51B -587M -7.32B -587M -575M -25.24B |
| Net Debt | -443M -3.48B -387M -356M -332M -629M -42.19B -639M -4.27B -1.66B -20.74B -1.66B -1.63B -71.47B | -387M -3.04B -338M -311M -290M -550M -36.87B -558M -3.73B -1.45B -18.12B -1.45B -1.42B -62.45B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-03 | HK$14.96 | -0.20% | 10,433,609 |
| 26-07-02 | HK$14.99 | +3.67% | 13,916,119 |
| 26-06-30 | HK$14.46 | +1.76% | 8,903,610 |
| 26-06-29 | HK$14.21 | +2.16% | 11,645,300 |
| 26-06-26 | HK$13.91 | -3.87% | 13,236,847 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ZLAB Stock
- 9688 Stock
Select your edition
All financial news and data tailored to specific country editions
